Shanghai Obio Technology (Group) Corp Ltd
688238
Company Profile
Business description
Shanghai Obio Technology (Group) Corp Ltd provides contract research organization (CRO) services, including gene therapy vector development and gene function research for basic research, as well as contract development and manufacturing organization (CDMO) services, including IND-enabling CMC research and GMP production of clinical samples for gene therapy drug development.
Contact
Lane 908, Ziping Road
Building 19
International Medical Park, Pudong New Area
Shanghai201318
CHNT: +86 2158585887
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
692
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,786.70 | 113.00 | -1.27% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,058.08 | 235.95 | -0.93% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,731.94 | 1,007.74 | -1.88% |
| NZX 50 Index | 12,881.17 | 55.30 | 0.43% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,590.40 | 94.60 | -1.09% |
| SSE Composite Index | 3,926.64 | 21.91 | -0.55% |